U.S. pharma big copyright scrapped two experimental weight loss drugs very last year—a after-daily tablet, lotiglipron, as a result of elevated liver enzymes in addition to a 2 times-every day tablet, danuglipron, as a consequence of robust Unwanted effects—but CEO Albert Bourla has